Two Italian kindreds carrying the Arg136→Ser mutation of the Apo E gene: Development of premature and severe atherosclerosis in the presence of epsilon 2 as second allele

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 13, Issue 2, 2003, Pages 93-99

  Rolleri, M ^a   Vivona, N ^b   Emmanuele, G ^c   Cefalu A B ^b   Pisciotta, L ^a   Guido, V ^a   Noto, D ^b   Fiore, B ^c   Barbagallo, C M ^b   Notarbartolo, A ^b   Travali, S ^c   Bertolini, S ^a   Averna, M R ^b,d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apo E gene mutation; ApoE Christchurch; Cardiovascular disease; Type III hyperlipoproteinemia

Indexed keywords

6 (GAMMA GLUTAMYL)LYSINE; APOLIPOPROTEIN E; ARGININE; LIPID; SERINE; APOLIPOPROTEIN E2;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ANGINA PECTORIS; ARTICLE; ATHEROGENESIS; CAROTID ARTERY DISEASE; CASE REPORT; CHROMOSOME BANDING PATTERN; CLINICAL EXAMINATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTENSION; MALE; MORTALITY; PEDIGREE ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SEGREGATION DISTORTION; SEQUENCE ANALYSIS; ARTERIOSCLEROSIS; BLOOD; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PEDIGREE; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY;

POMACANTHUS MACULOSUS;

ALLELES; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BASE SEQUENCE; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; LIPIDS; MALE; MIDDLE AGED; MUTATION; PEDIGREE; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY;

EID: 0642307080     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-4753(03)80024-8     Document Type: Article

References (23)

1. Wardell MR, Brennan SO, Janus ED, Fraser R, Carrell RW (1987) Apolipoprotein E2-Christchurch (136 Arg→Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J Clin Invest 80: 483-490
2. Emi M, Wu LL, Robertson MA, Myers RL, Hegele RA, Williams RR, White R, Lalouel JM (1988) Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics 3: 373-379
3. Pocovi M, Cenarro A, Civeira F, Myers RH, Cassao E, Esteban M, Ordovas JM (1996) Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136→Ser) variant in multigenerational pedigree studies. Atherosclerosis 122: 33-46
4. Civeira F, Pocovi M, Cenarro A, Casao E, Vilella E, Joven J, Gonzalez J, Garcia-Otin AL, Ordovas JM (1996) Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis 127: 273-282
5. Valveny N, Esteban E, Kandil M, Moral P (1997) Apo E polymorphism in Spanish and Moroccan populations. Clin Genet 51: 354-356
6. Feussner G, Feussner V, Hoffmann MM, Lohrmann J, Wieland H, März W (1998) Molecular basis of type III hyperlipoproteinemia in Germany. Hum Mutat 11: 417-423
7. Hegele RA (1999) Uncovering rare mutations: an unforeseen complication of routine genotyping of APOE. Clin Chem 45: 1579-1581
8. Vialettes B, Reynier P, Atlan-Gepner C, Mekki N, Lesluyes-Mazzocchi L, Luc G, Lairon D, Malthiery Y (2000) Dietary fat clearance in type V hyperlipoproteinemia secondary to a rare variant of human apolipoprotein E: the apolipoprotein E3 (Arg136→Ser). Br J Nutr 83: 615-622
9. Roschlau P (1974) Enzymatische bestimmung des gesamte-cholesterins in serum. Chem Klin Biochem 12: 226-227
10. Wahalefeld AW (1974) Triglyceride determination after enzymatic hydrolysis. In: Bergmeyer HU (ed) Methods of Enzymatic Analysis (vol 4), Academic Press, New York, pp 1831-1835
11. Lopez-Virella HF, Stone P, Ellis J, Coltwell LA (1970) Cholesterol determination in the HDL separated by precipitation with polianions. J Lipid Res 11: 583-595
12. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31: 545-548
13. Garcia-Otin AL, Civeira F, Aristegui R, Diaz C, Recalde D, Sol JM, Masramon X, Hernandez G, Pocovi M (2002) Allelic polymorphism -491 A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. Eur J Clin Invest 32: 421-428
14. Stengård JH, Clark AG, Weiss KM, Kardia S, Nickerson DA, Salomaa V, Ehnholm C, Boerwinkle E, Sing CF (2002) Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism. Am J Hum Genet 71: 501-517
15. Ji ZS, Fazio S, Mahley RW (1994) Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem 269: 13421-13428
16. Lalazar A, Weisgraber KH, Rall SC Jr, Giladi H, Innerarity TL, Levanon AZ, Boyles JK, Amit B, Gorecki M, Mahley RW (1988) Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem 263: 3542-3545
17. Dart A, Sherrard B, Simpson H (1997) Influence of apo E phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary heart disease. Atherosclerosis 130: 161-170
18. Dallongeville J, Tiret L, Visvikis S, O'Reilly DS, Saava M, Tsitouris G, Rosseneu M, DeBacker G, Humphries SE, Beisiegel U (1999) Effect of apo E phenotype on plasma postprandial triglyceride levels in young male adults with and without a family history of myocardial infarction: the EARS II study. European Atherosclerosis Research Study. Atherosclerosis 145: 381-388
19. Walden CC, Huff MW, Leiter LA, Connelly PW, Hegele RA (1994) Detection of a new apolipoprotein-E mutation in type III hyperlipoproteinemia using deoxyribonucleic acid restriction typing. J Clin Endocrinol Metab 78: 699-704
20. Feussner G, Albanese M, Mann WA, Valencia A, Schuster H (1996) Apolipoprotein E2 (Arg136→Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinemia. Eur J Clin Invest 26: 13-23
21. März W, Hoffmann MM, Scharnagl H, Fisher E, Chen M, Nauck M, Feussner G, Wieland H (1998) Apolipoprotein E2 (Arg136→Cys) mutation in the receptor binding domain of apo E is not associated with dominant type III hyperlipoproteinemia. J Lipid Res 39: 658-669
22. Hubacek JA, Pitha J, Stavek P, Schmitz G, Poledne R (2000) Variable expression of hypercholesterolemia in Apolipoprotein E2* (Arg136→Cys). Physiol Res 49: 307-314
23. Minnich A, Weisgraber KH, Newhouse Y, Dong LM, Fortin LJ, Tremblay M, Davignon J (1995) Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136→His): association with mild dyslipidemia and double pre-β very low density lipoproteins. J Lipid Res 36: 57-66